# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate o...
Oppenheimer analyst Leland Gershell maintains Protara Therapeutics (NASDAQ:TARA) with a Outperform and raises the price targ...
HC Wainwright & Co. analyst Andrew Fein maintains Protara Therapeutics (NASDAQ:TARA) with a Buy and maintains $23 price ...
Explore TARA-002's data in NMIBC treatment. Discover findings from three trials, including response rates, adverse events, ...
Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of can...